TMPRSS2 and prostate adenocarcinoma: The following groups of comparisons were formed: (1) BCR versus BRF cases within the TMPRSS2–ERG molecular subtype and (2) BCR versus BRF cases within the TMPRSS2–ERG molecular subtype in the TCGA–PRAD cohort.